文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

富含组氨酸糖蛋白下降作为预测全身炎症反应综合征患者脓毒症的新型生物标志物

Decrease in Histidine-Rich Glycoprotein as a Novel Biomarker to Predict Sepsis Among Systemic Inflammatory Response Syndrome.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论单中心前瞻性队列显示,SIRS患者中脓毒症者血浆富含组氨酸糖蛋白水平显著降低,其诊断脓毒症的AUC为0.97,可能优于降钙素原和Presepsin。

本研究为单中心前瞻性观察性队列,纳入79例ICU患者(70例SIRS,9例非SIRS)和16名健康志愿者,入住ICU 24小时内采血测富含组氨酸糖蛋白、降钙素原和Presepsin。SIRS患者富含组氨酸糖蛋白中位数28.72 µg/mL,低于非SIRS患者的38.64 µg/mL(p=0.049)。70例SIRS中20例脓毒症,脓毒症患者富含组氨酸糖蛋白为8.71 µg/mL,低于非感染性SIRS的33.27 µg/mL(p<0.001);SIRS死亡者(n=8)为9.06 µg/mL,低于存活者(n=62)的31.78 µg/mL(p<0.001)。诊断脓毒症的ROC曲线下面积:富含组氨酸糖蛋白0.97、降钙素原0.82、Presepsin 0.77;生存分析Harrell C-index分别为0.85、0.65、0.87。结论认为富含组氨酸糖蛋白在脓毒症中降低并与死亡率相关,作为生物标志物可能优于降钙素原和Presepsin。

要点

  • SIRS患者中,脓毒症者血浆富含组氨酸糖蛋白中位数8.71 µg/mL,显著低于非感染性SIRS者的33.27 µg/mL(p<0.001)。
  • SIRS患者中,死亡者(n=8)富含组氨酸糖蛋白中位数9.06 µg/mL,显著低于存活者(n=62)的31.78 µg/mL(p<0.001)。
  • 诊断SIRS中脓毒症的ROC曲线下面积:富含组氨酸糖蛋白0.97,降钙素原0.82,Presepsin 0.77。
  • SIRS患者生存分析的Harrell C-index:富含组氨酸糖蛋白0.85,降钙素原0.65,Presepsin 0.87。
  • 健康志愿者(n=16)富含组氨酸糖蛋白中位数为63.00 µg/mL(IQR 51.53-66.21 µg/mL)。

适用人群与场景

  • ICU患者,包括70例全身炎症反应综合征(SIRS)患者和9例非SIRS患者,以及16名健康志愿者。
  • 血样在入住ICU 24小时内采集。

研究设计与关键结果

  • 研究类型:单中心、前瞻性、观察性队列研究,纳入79例ICU患者(70例SIRS,9例非SIRS)和16名健康志愿者。
  • SIRS患者富含组氨酸糖蛋白中位数28.72 µg/mL(IQR 15.74-41.46 µg/mL),低于非SIRS患者的38.64 µg/mL(IQR 30.26-51.81 µg/mL),p=0.049。
  • 70例SIRS患者中20例脓毒症,脓毒症患者富含组氨酸糖蛋白中位数8.71 µg/mL(IQR 6.72-15.74 µg/mL),低于非感染性SIRS患者的33.27 µg/mL(IQR 26.57-44.99 µg/mL),p<0.001。
  • SIRS死亡者(n=8)富含组氨酸糖蛋白中位数9.06 µg/mL(IQR 4.49-15.70 µg/mL),低于存活者(n=62)的31.78 µg/mL(IQR 18.57-42.11 µg/mL),p<0.001。
  • 诊断SIRS中脓毒症的ROC曲线下面积:富含组氨酸糖蛋白0.97,降钙素原0.82,Presepsin 0.77。
  • SIRS患者生存分析的Harrell C-index:富含组氨酸糖蛋白0.85,降钙素原0.65,Presepsin 0.87。

证据类型、等级与局限

  • 证据类型:单中心、前瞻性、观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ICU收治的SIRS患者中,血浆富含组氨酸糖蛋白水平降低可能提示脓毒症和死亡风险升高;作者认为其作为生物标志物可能优于降钙素原和Presepsin。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Many biomarkers for sepsis are used in clinical practice; however, few have become the standard. We measured plasma histidine-rich glycoprotein levels in patients with systemic inflammatory response syndrome. We compared histidine-rich glycoprotein, procalcitonin, and presepsin levels to assess their significance as biomarkers.

DESIGN: Single-center, prospective, observational cohort study.

SETTING: ICU at an university-affiliated hospital.

PATIENTS: Seventy-nine ICU patients (70 with systemic inflammatory response syndrome and 9 without systemic inflammatory response syndrome) and 16 healthy volunteers.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We collected blood samples from patients within 24 hours of ICU admission. Histidine-rich glycoprotein levels were determined using enzyme-linked immunosorbent assay. The median histidine-rich glycoprotein level in healthy volunteers (n = 16) was 63.00 µg/mL (interquartile range, 51.53-66.21 µg/mL). Histidine-rich glycoprotein levels in systemic inflammatory response syndrome patients (n = 70; 28.72 µg/mL [15.74-41.46 µg/mL]) were lower than those in nonsystemic inflammatory response syndrome patients (n = 9; 38.64 µg/mL [30.26-51.81 µg/mL]; p = 0.049). Of 70 patients with systemic inflammatory response syndrome, 20 had sepsis. Histidine-rich glycoprotein levels were lower in septic patients than in noninfective systemic inflammatory response syndrome patients (8.71 µg/mL [6.72-15.74 µg/mL] vs 33.27 µg/mL [26.57-44.99 µg/mL]; p < 0.001) and were lower in nonsurvivors (n = 8) than in survivors (n = 62) of systemic inflammatory response syndrome (9.06 µg/mL [4.49-15.70 µg/mL] vs 31.78 µg/mL [18.57-42.11 µg/mL]; p < 0.001). Histidine-rich glycoprotein showed a high sensitivity and specificity for diagnosing sepsis. Receiver operating characteristic curve analysis for detecting sepsis within systemic inflammatory response syndrome patients showed that the area under the curve for histidine-rich glycoprotein, procalcitonin, and presepsin was 0.97, 0.82, and 0.77, respectively. In addition, survival analysis in systemic inflammatory response syndrome patients revealed that the Harrell C-index for histidine-rich glycoprotein, procalcitonin, and presepsin was 0.85, 0.65, and 0.87, respectively.

CONCLUSIONS: Histidine-rich glycoprotein levels were low in patients with sepsis and were significantly related to mortality in systemic inflammatory response syndrome population. Furthermore, as a biomarker, histidine-rich glycoprotein may be superior to procalcitonin and presepsin.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kuroda K, Wake H, Mori S, et al. Decrease in Histidine-Rich Glycoprotein as a Novel Biomarker to Predict Sepsis Among Systemic Inflammatory Response Syndrome. Crit Care Med. 2018. PMID: 29303798. doi:10.1097/CCM.0000000000002947

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。